NR3C2 and heart failure: Our cohort can be considered a contemporary cohort, because treatment with mineralocorticoid receptor antagonists26, 27 and angiotensin receptor‐neprilysin inhibitors28 was available during the study course, although no patient was treated with angiotensin‐receptor‐neprilysin inhibitors at initiation of the study; as it was only recommended by major heart failure guidelines in 2016.29